Vestal Point Capital, LP Astria Therapeutics, Inc. Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
A detailed history of Vestal Point Capital, LP transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vestal Point Capital, LP holds 4,180,000 shares of ATXS stock, worth $29.4 Million. This represents 2.22% of its overall portfolio holdings.
Number of Shares
4,180,000
Previous 4,000,000
4.5%
Holding current value
$29.4 Million
Previous $44 Billion
15.15%
% of portfolio
2.22%
Previous 3.34%
Shares
4 transactions
Others Institutions Holding ATXS
# of Institutions
115Shares Held
50.3MCall Options Held
75KPut Options Held
6.2K-
Perceptive Advisors LLC New York, NY6.49MShares$45.6 Million1.91% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$35.9 Million0.73% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$25 Million6.29% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$24.7 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.87MShares$20.2 Million4.34% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $107M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...